NCI-H1703 / NCI-H1703-luc Orthotopic Mouse Model Service for Lung Cancer

The NCI-H1703 / NCI-H1703-luc orthotopic mouse model of lung cancer carries a bona fide FGFR1-amplified human squamous cell carcinoma into the thoracic cavity, pairing true lung-site tumor biology with quantitative luciferase bioluminescence that tracks locally invasive disease and treatment response in real time. Alfa Cytology delivers this model as an end-to-end preclinical service — from authenticated CRL-5889 banking and luciferase line qualification through intrathoracic implantation in nude recipients, scheduled whole-body imaging, treatment dosing, and endpoints spanning thoracic tumor burden, dissemination scoring, FGFR-pathway pharmacodynamics, and histopathology.

Overview of NCI-H1703 / NCI-H1703-luc Orthotopic Mouse Model for Lung Cancer

NCI-H1703 is a human squamous cell lung carcinoma line deposited with ATCC as CRL-5889, established in 1987 by A. F. Gazdar and J. D. Minna from the lung of a 54-year-old male patient with non-small cell lung cancer and a significant smoking history. Its defining molecular feature is amplification of FGFR1 — a lesion found in roughly 10-20% of squamous NSCLC and one of the most actionable alterations in this histology — which drives constitutive FGFR signaling and renders the line demonstrably dependent on the pathway. Among squamous NSCLC lines profiled for FGFR inhibitor response, NCI-H1703 ranks among the most sensitive, with sub-micromolar IC50 values to selective FGFR inhibitors such as CPL304110 and responsiveness to PD173074-class agents; the resistant derivative NCI-H1703R, selected under drug pressure, has served to map acquired resistance, revealing upregulation of p38 MAPK signaling that restores sensitivity when blocked. Phenotypically, the cells grow as adherent epithelial monolayers and display a highly invasive, non-spheroid growth pattern in three-dimensional culture — a behavioral hallmark that translates into aggressive local behavior in vivo.

Fig 1. Growth of orthotopic NSCLC of three different cell lines (Upper-NCI-H1703, middle-NCI-H23 and lower-A549) assessed by BLI and CBCT. (Aktar, Rozina, et al., 2019)

Orthotopically, NCI-H1703-luc cells are implanted into the thoracic cavity of athymic nude mice — by intrathoracic injection into the mediastinal region, the route pioneered in the luciferase-orthotopic literature — where they establish locally invasive tumors that recapitulate advanced lung cancer’s confined, organ-threatening growth. Serial whole-body bioluminescence imaging after D-luciferin administration resolves tumor burden from first engraftment onward, and in the analogous published orthotopic system untreated disease runs its course within weeks, with chemotherapeutic and radiation reference regimens producing measurable signal suppression and survival benefit. For FGFR1-amplified programs, this model supplies what flank xenografts cannot: a thoracic environment in which FGFR-dependence, local invasion, and resistance emergence can be interrogated together, supporting inhibitor benchmarking, combination strategies pairing FGFR blockade with p38-pathway modulation, radiation-response studies, and imaging-method development for thoracic oncology.

Cell Line Information: NCI-H1703 / NCI-H1703-luc

NCI-H1703 is a cornerstone squamous NSCLC line in FGFR research, with documented STR identity and a well-characterized drug-response profile. Its luciferase derivative enables imaging-guided orthotopic studies. Core attributes follow.

Our Services

FGFR1-amplified squamous disease is one of the most actively pursued niches in thoracic oncology, and the value of an NCI-H1703-luc study rises or falls with how faithfully the model’s FGFR-dependence and invasive character are preserved. Alfa Cytology protects both: authenticated CRL-5889 stocks with capped passage, reporter lines released only after uniform luminescence is confirmed, and intrathoracic implantation executed under written technique with immediate imaging verification. Dosing arms, imaging calendars, and endpoint panels are then configured to each sponsor’s mechanism — whether a selective FGFR inhibitor, an FGFR-plus-p38 combination, or a radiation-interaction study — so that every NCI-H1703 / NCI-H1703-luc orthotopic cohort returns interpretable, decision-grade data.

Workflow of NCI-H1703 / NCI-H1703-luc Orthotopic Mouse Model Construction

The NCI-H1703-luc orthotopic workflow follows the proven intrathoracic paradigm of luciferase-orthotopic lung modeling, tightened with signal-verified randomization and FGFR-pathway-aware endpoints. The sequence below runs from cell release to final histopathology.

1. Authentication and reporter release: NCI-H1703 / NCI-H1703-luc stocks are expanded from authenticated CRL-5889 master banks at capped passage, mycoplasma-tested, and released only after uniform firefly luciferase expression is confirmed by serial in vitro luminescence assay.
2. Inoculum preparation: Log-phase adherent cultures are released with trypsin/EDTA, washed, counted, and resuspended in sterile DPBS at about 3×10⁶ cells in 100 µL per mouse.
3. Recipient preparation: Athymic nude mice are acclimatized, body-weight stratified, anesthetized with isoflurane, and positioned with chest disinfection and thermal support.
4. Intrathoracic implantation: A fine needle is advanced at roughly 45 degrees alongside the sternum to shallow depth, and the suspension is delivered into the mediastinal/thoracic region; immediate post-injection imaging localizes thoracic signal, verifying correct deposition.
5. Recovery and baseline imaging: Animals recover under monitoring, and baseline whole-body bioluminescence after intraperitoneal D-luciferin (100-150 mg/kg) documents engraftment and starting photon flux.
6. Serial imaging and randomized dosing: Thoracic photon flux is tracked on a fixed schedule alongside body weight and respiratory clinical signs; cohorts are randomized by matched baseline signals, and dosing begins — FGFR inhibitors, combinations, chemotherapy, or thoracic radiation per study design.
7. Terminal workup and pathway analysis: At endpoint, thoracic tumors are excised and weighed, lungs and mediastinum are inspected and imaged ex vivo, dissemination is scored, and tissues undergo H&E plus FGFR-pathway and p38-MAPK immunohistochemistry to confirm squamous histology and capture on-target pharmacodynamics.

Fig 2. NCI-H1703 / NCI-H1703-luc orthotopic mouse model construction workflow.

Case Study-NCI-H1703 / NCI-H1703-luc Orthotopic Mouse Model Development

Alfa Cytology has implemented the NCI-H1703 orthotopic platform for sponsors pursuing FGFR-directed inhibitors, FGFR-plus-p38 combination strategies, and radiation-interaction studies in squamous NSCLC. In these programs, serial thoracic bioluminescence captured locally invasive tumor kinetics and quantified treatment-induced signal suppression against matched baselines, randomized arms started from equivalent photon flux, and terminal analyses combined tumor weights with ex vivo thoracic imaging and FGFR-pathway immunohistochemistry. Where designs required it, p38-status assessment was incorporated to contextualize response durability. Study-specific parameters and outcomes are retained as sponsor-confidential deliverables, and illustrative outlines can be furnished on request.

Why Choose Alfa Cytology?

FGFR1-amplified disease places special demands on a thoracic model — the tumor must keep its invasive character, its pathway dependence, and its imaging tractability all at once. Alfa Cytology’s NCI-H1703-luc service is organized to hold all three steady through every study phase. Sponsors benefit from:

• Authenticated CRL-5889 stocks at capped passage with STR-documented identity.
• Reporter lines qualified for uniform luciferase output before release into studies.
• Written intrathoracic implantation technique with immediate post-injection imaging verification.
• Signal-matched randomization for balanced arms in confined thoracic disease.
• FGFR-pathway-aware endpoint panels, including p38-MAPK contextualization where relevant.
• Compatibility with chemotherapy and thoracic radiation reference regimens from published orthotopic practice.
• Single-point study accountability with per-timepoint reporting from implantation to final analysis.

Contact Us

Advancing an FGFR1-amplified squamous NSCLC program and need a thoracic model with imaging-grade readouts? Contact us to discuss implantation approach, imaging cadence, and endpoint design for the NCI-H1703 / NCI-H1703-luc orthotopic platform. You can also reach out to Alfa Cytology for a customized study proposal and quotation — our team will respond promptly with a design aligned to your therapeutic strategy.

For research use only. Not intended for any clinical use.